Nanotechnology applications for improved delivery of antiretroviral drugs to the brain

Advanced Drug Delivery Reviews

Volumn 62, Issue 4-5, 2010, Pages 503-517

  Wong, Ho Lun ^a   Chattopadhyay, Niladri ^b   Wu, Xiao Yu ^b   Bendayan, Reina ^b  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antiretroviral; ATP binding cassette membrane transporters; Blood brain barrier; Brain delivery; Human immunodeficiency virus; Nanotechnology

Indexed keywords

ANTIRETROVIRALS; ATP-BINDING CASSETTE; ATP-BINDING CASSETTE MEMBRANE TRANSPORTERS; BLOOD-BRAIN BARRIER; BRAIN DELIVERY; HUMAN IMMUNODEFICIENCY VIRUS;

BINDING SITES; BIOCHEMISTRY; BLOOD; LIPOSOMES; NANOPARTICLES; NANOTECHNOLOGY; PHOSPHOLIPIDS; TRANSPORT PROPERTIES;

VIRUSES;

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CISPLATIN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ELACRIDAR; EMTRICITABINE; ETOPOSIDE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LIPOSOME; LOPINAVIR; NANOCARRIER; NANOPARTICLE; NELFINAVIR; NEVIRAPINE; POLYMER; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SOLID LIPID NANOPARTICLE; STAVUDINE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD CEREBROSPINAL FLUID BARRIER; CENTRAL NERVOUS SYSTEM INFECTION; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TRANSPORT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICELLE; NANOTECHNOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; VIRUS REPLICATION;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; BRAIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HIV INFECTIONS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY;

EID: 76849112146     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.11.020     Document Type: Review

References (194)

1. Freed E.O. HIV-1 replication. Somat. Cell Mol. Genet. 26 (2001) 13-33
2. Wyatt R., and Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280 (1998) 1884-1888
3. Chan D., and Kim P. HIV entry and its inhibition. Cell 93 (1998) 681-684
4. Joint United Nations Programme on HIV/AIDS, World Health Organization (WHO), AIDS epidemic update: December 2007. http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf. Retrieved on 2009-05-18.
5. Dalgliesh A.G., Beverley P.C.L., Clapman P.R., Crawford D.H., Greaves M.F., and Weiss R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312 (1984) 767-768
6. Kolchinsky P., Kiprilov E., and Sodroski J. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J. Virol. 75 (2001) 2041-2050
7. Martin J., LaBranche C.C., and Gonzalez-Scarano F. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate. J. Virol. 75 (2001) 3568-3580
8. Nermut M.V., and Fassati A. Structural analyses of purified human immunodeficiency virus type 1 intracellular reverse transcription complexes. J. Virol. 77 (2003) 8196-8206
9. Bagasra O.E., Lavi L., Bobroski K., Khalili J.P., Pestaner R., Tawadros R., and Pomerantz R.J. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 10 (1996) 573-585
10. Chen H., Wood C., and Petito C.K. Comparisons of HIV-1 viral sequences in brain, choroid plexus and spleen: Potential role of choroid plexus in the pathogenesis of HIV encephalitis. J. NeuroVirol. 6 (2000) 498-506
11. González-Scarano F., and Martín-García J. The neuropathogenesis of AIDS. Nature Rev. Immunol. 5 (2005) 69-81
12. Asensio V.C., and Campbell I.L. Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci. 22 (1999) 504-512
13. Kaul M., and Lipton S.A. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 8212-8216
14. Ronaldson P.T., and Bendayan R. HIV-1 viral envelope glycoprotein gp120 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. Mol. Pharmacol. 70 (2006) 1087-1098
15. New D.R., Ma M., Epstein L.G., Nath A., and Gelbard H.A. Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures. J. Neurovirol 3 (1997) 168-173
16. De Noronha C.M., Sherman M.P., Lin H.W., Cavrois M.V., Moir R.D., Goldman R.D., and Greene W.C. Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 294 (2001) 1105-1108
17. Kaul M., Zheng J., Okamoto S., Gendelman H.E., and Lipton S.A. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ. 12 (2005) 878-892
18. Dreyer E.B., Kaiser P.K., Offermann J.T., and Lipton S.A. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 248 (1990) 364-367
19. Adamson D.C., Wildemann B., Sasaki M., Glass J.D., McArthur J.C., Christov V.I., Dawson T.M., and Dawson V.L. Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. Science 274 (1996) 1917-1921
20. Song L., Nath A., Geiger J.D., Moore A., and Hochman S. Human immunodeficiency virus type 1 tat protein directly activates neuronal N-methyl-D-aspartate receptors at an allosteric zinc-sensitive site. J. Neurovirol. 9 (2003) 399-403
21. Kanmogne G.D., Kennedy R.C., and Grammas P. HIV-1 gp120 proteins and gp160 peptides are toxic to brain endothelial cells and neurons: possible pathway for HIV entry into the brain and HIV-associated dementia. J. Neuropathol. Exp. Neurol. 61 (2002) 992-1000
22. Ricardo-Dukelow M., Kadiu I., Rozek W., Schlautman J., Persidsky Y., Ciborowski P., Kanmogne G., and Gendelman H. HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: new insights into blood-brain barrier dysfunction for HIV-1-associated dementia. J. Neuroimmunol. 185 (2007) 37-46
23. Trillo-Pazos G., Diamanturos A., Rislove L., Menza T., Chao W., Belem P., Sadiq S., Morgello S., Sharer L., and Volsky D.J. Detection of HIV-1 DNA in microglia/macrophages, astrocytes and neurons isolated from brain tissue with HIV-1 encephalitis by laser capture microdissection. Brain Pathol. 13 (2003) 144-154
24. Liu Y., Liu H., Kim B.O., Gattone V.H., Li J., Nath A., Blum J., and He J.J. CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor. J. Virol. 78 (2004) 4120-4133
25. Levy R.M., and Berger J.R. HIV-related central nervous system disorders. In: Tindall G.T., Cooper P.R., and Barrow D.L. (Eds). The Practice of Neurosurgery (1997), William and Wilkins chapter 228
26. Sacktor N., Lyles R.H., Skolasky R., Kleeberger C., Selnes O.A., Miller E.N., Becker J.T., Cohen B., and McArthur J.C. HIV-associated neurologic disease incidence changes: multicenter AIDS cohort study, 1990-1998. Neurol. 56 (2001) 257-260
27. Ellis R.J., Deutsch R., Heaton R.K., Marcotte T.D., McCutchan J.A., Nelson J.A., Abramson I., Thal L.J., Atkinson J.H., Wallace M.R., and Grant I. Neurocognitive impairment is an independent risk factor for death in HIV infection. Arch. Neurol. 54 (1997) 416-424
28. Maher J., Choudhri S., Halliday W., Power C., and Nath A. AIDS dementia complex with generalized myoclonus. Mov. Disord. 12 (1997) 593-597
29. Lyketsos C.G., Schwartz J., Fishman M., and Treisman G. AIDS mania. J. Neuropsychiatry Clin. Neurosci. 9 (1997) 277-279
30. Yarchoan R., Mitsuya H., and Broder S. AIDS therapies. Sci. Am. 259 (1988) 110-119
31. Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Health and Human Services, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents November 3, 2008; 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 05-22-09.
32. Hammer S.M., Eron Jr. J.J., Reiss P., Schooley R.T., Thompson M.A., Walmsley S., Cahn P., Fischl M.A., Gatell J.M., Hirsch M.S., Jacobsen D.M., Montaner J.S., Richman D.D., Yeni P.G., and Volberding P.A. International AIDS Society-USA, Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300 (2008) 555-570
33. Kerza-Kwiatecki A.P., and Amini S. AIDS program panel meeting on CNS as an HIV-1 reservoir: BBB and drug delivery, September, 1998. J. Neurovirol. 5 (1999) 113-114
34. Ghafouri M., Amini S., Khalili K., and Sawaya B.E. HIV-1 associated dementia: symptoms and causes. Retrovirology 3 (2006) 28
35. McArthur J.C., Haughey N., Gartner S., Conant K., Pardo C., Nath A., and Sacktor N. Human immunodeficiency virus-associated dementia: an evolving disease. J. Neurovirol. 9 (2003) 205-221
36. Clifford D.B. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med. 16 (2008) 94-98
37. Tozz V., Balestra P., Bellagamba R., Corpolongo A., Salvatori M.F., Vlassi C., Giulianelli M., Galgani S., Antinori A., and Narciso P. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J. Acquir. Immune Defic. Syndr. 45 (2007) 174-182
38. Ances B.M., and Ellis R.J. Dementia and neurocognitive disorders due to HIV-1 infection. Semin. Neurol. 27 (2007) 86-92
39. Wong J.K., Ignacio C.C., Torriani F., Havlir D., Fitch N.J., and Richman D.D. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J. Virol. 71 (1997) 2059-2071
40. Blankson J.N., Persaud D., and Siliciano R.F. The challenge of viral reservoirs in HIV-1 infection. Ann. Rev. Med. 53 (2002) 557-593
41. Chun T.K., Justement J.S., Moir S., Hallahan C.W., Meenze J., Mullins J.I., Collier A.C., Corey L., and Fauci A.S. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implication for eradication of virus. J. Infect. Dis. 195 (2007) 1762-1764
42. McGee B., Smith N., and Aweeka F. HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin. Trials 7 (2006) 142-153
43. Temesgen Z., Warnke D., and Kasten M.J. Current status of antiretroviral therapy. Expert Opin. Pharmacother. 7 (2006) 1541-1554
44. Oldfield V., and Plosker G.L. Lopinavir/ritonavir: a review of its use in the management of HIV infection 66 (2006) 1275-1299
45. Perry C.M., Frampton J.E., McCormack P.L., Siddiqui M.A., and Cvetkovic R.S. Nelfinavir: a review of its use in the management of HIV infection. Drugs 65 (2005) 2209-2244
46. Swainston H.T., and Scott L.J. Atazanavir: a review of its use in the management of HIV infection. Drugs 65 (2005) 2309-2336
47. Wynn H.E., Brundage R.C., and Fletcher C.V. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 16 (2002) 595-609
48. Thomas S.A. Anti-HIV drug distribution to the central nervous system. Curr. Pharm. Design 10 (2004) 1313-1324
49. Smith D.E., Johanson C.E., and Keep R.F. Peptide and peptide analog transport systems at the blood-CSF barrier. Adv. Drug Deliv. Rev. 56 (2004) 1765-1791
50. Yousif S., Marie-Claire C., Roux F., Scherrmann J.M., and Decleves X. Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy. Brain Res. 1134 (2007) 1-11
51. Hamilton R.D., Foss A.J., and Leach L. Establishment of a human in vitro model of the outer blood-retinal barrier. J. Anat. 211 (2007) 707
52. Kusuhara H., and Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (part 1). Drug Discov. Today 6 (2001) 150-156
53. González-Mariscal L., Betanzos A., Nava P., and Jaramillo B.E. Tight junction proteins. Prog. Biophys. Mol. Biol. 81 (2003) 1-44
54. Davson H., Welch K., and Segal M.B. The physiology and pathophysiology of the cerebrospinal fluid (1987), Churchill Livingstone, London 375-453
55. Gimenez F., Fernandez C., and Mabondzo A. Transport of HIV protease inhibitors through the blood-brain: interactions of P-glycoprotein and HIV protease inhibitors. J. Acquir. Immune Defic. Syndr. 36 (2004) 649-658
56. Dean M., Rzhetsky A., and Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11 (2001) 1156-1166
57. M. Dean, National Library of Medicine (US), NCBI, The human ATP-binding cassette (ABC) transporter superfamily. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=mono_001&part=A137. 2002, Accessed 05-24-09.
58. Hollenstein K., Frei D.C., and Locher K.P. Structure of an ABC transporter in complex with its binding protein. Nature 446 (2007) 213-216
59. Juliano R.L., and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 455 (1976) 152-162
60. Krishna R., and Mayer L.D. Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11 (2000) 265-283
61. Sharom F.J. Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem. Cell Biol. 84 (2006) 979-992
62. Dallas S., Miller D.S., and Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol. Rev. 58 (2006) 140-161
63. Mayer R., Kartenbeck J., Buchler M., Jedlitschky G., Leier I., and Keppler D. Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport- deficient mutant hepatocytes. J. Cell Biol. 131 (1995) 137-150
64. Evers R., Kool M., van Deemter L., Janssen H., Calafat J., Oomen L.C., Paulusma C.C., Oude Elferink RP R.P., Baas F., Schinkel A.H., and Borst P. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 101 (1998) 1310-1319
65. Doyle L.A., Yang W., and Abruzzo L.V. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl. Acad. Sci. USA 95 (1998) 15665-15670
66. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., van De Vijver M.J., Scheper R.J., and Schellens J.H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61 (2001) 3458-3464
67. Janneh O., Jones E., Chandler B., Owen A., and Khoo S.H. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J. Antimicrob. Chemother. 60 (2007) 987-993
68. Jones K., Bray P.G., Khoo S.H., Davey R.A., Meaden E.R., Ward S.A., and Back D.J. P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance. AIDS 15 (2001) 1353-1358
69. Ronaldson P.T., Lee G., Dallas S., and Bendayan R. Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines. Pharm. Res. 21 (2004) 811-818
70. Lee C.G., Gottesman M.M., Cardarelli C.O., Ramachandra M., Jeang K.T., Ambudkar S.V., Pastan I., and Dey S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37 (1998) 3594-3601
71. Washington C.B., Wiltshire H.R., Man M., Moy T., Harris S.R., Worth E., Weigl P., Liang Z., Hall D., Marriott L., and Blaschke T.F. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab. Dispos. 28 (2000) 1058-1062
72. Janneh O., Owen A., Chandler B., Hartkoorn R.C., Hart C.A., Bray P.G., Ward S.A., Back D.J., and Khoo S.H. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 19 (2005) 2097-2102
73. Dallas S., Ronaldson P.T., Bendayan M., and Bendayan R. Multidrug resistance protein 1-mediated transport of saquinavir by microglia. Neuroreport 15 (2004) 1183-1186
74. Dallas S., Zhu X., Baruchel S., Schlichter L., and Bendayan R. Functional expression of the multidrug resistance protein 1 in microglia. J. Pharmacol. Exp. Ther. 307 (2003) 282-290
75. Bendayan R., Lee G., and Bendayan M. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc. Res. Tech. 57 (2002) 365-380
76. Lee G., Schlichter L., Bendayan M., and Bendayan R. Functional expression of P-glycoprotein in rat brain microglia. J. Pharmacol. Exp. Ther. 299 (2001) 204-212
77. Perloff E.S., Duan S.X., Skolnik P.R., Greenblatt D.J., and Von Moltke L.L. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab. Dispos. 33 (2005) 764-770
78. Perloff M.D., Stormer E., Von Moltke L.L., and Greenblatt D.J. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm. Res. 20 (2003) 1177-1183
79. Perloff M.D., Moltke L.L., and Greenblat D.J. Fexofenadine transport in Caco-2 cells: Inhibition with verapamil and ritonavir. J. Clin. Pharmacol. 42 (2002) 1269-1274
80. Gupta S., Campbell D., Derijard B., and Davis R.J. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267 (1995) 389-393
81. Weiss J., Theile D., Ketabi-Kiyanvash N., Lindenmaier H., and Haefeli W.E. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab. Dispos. 35 (2007) 340-344
82. Storch C.H., Theile D., Lindenmaier H., Haefeli W.E., and Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem. Pharmacol 73 (2007) 1573-1581
83. Schuetz J.D., Connelly M.C., Sun D., Paibir S.G., Flynn P.M., Srinivas R.V., Kumar A., and Fridland A. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5 (1999) 1048-1051
84. Reid G., Wielinga P., Zelcer N., de Haas M., Van Deemter L., Wijnholds J., Balzarini J., and Borst P. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol. Pharmacol. 63 (2003) 1094-1103
85. Ronaldson P.T., Persidsky Y., and Bendayan R. Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection. GLIA 56 (2008) 1711-1735
86. Miller D.S., Nobmann S.N., Gutmann H., Toeroek M., Drewe J., and Fricker G. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol. Pharmacol. 58 (2002) 1357-1367
87. Ronaldson P.T., Bendayan M., Gingras D., Piquette-Miller M., and Bendayan R. Cellular localization and functional expression of P-glycoprotein in rat astrocyte cultures. J. Neurochem. 89 (2004) 788-800
88. Giri N., Shaik N., Pan G., Terasaki T., Mukai C., Kitagaki S., Miyakoshi N., and Elmquist W.F. Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metab. Disp. 36 (2008) 1476-1484
89. Choo E.F., Leake B., Wandel C., Imamura H., Wood A.J., Wilkinson G.R., and Kim R.B. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug. Metab. Dispos. 28 (2000) 655-660
90. Park S., and Sinko P.J. P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J. Pharmacol. Exp. Ther. 312 (2005) 1249-1256
91. Salama N.N., Kelly E.J., Bui T., and Ho R.J. The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice. J. Pharm. Sci. 94 (2005) 1216-1225
92. Salahuddin T.S., Johansson B.B., Kalimo H., Johansson B.B., and Olsson Y. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions: a light microscopic and immunohistochemical study. Neuropathol. Appl. Neurobiol. 14 (1988) 467-482
93. Neuwelt E.A., Hill S.A., and Frenkel E.P. Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening. Neurosurgery 15 (1984) 362-366
94. Fortin D., Gendron C., Boudrias M., and Garant M.P. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis. Cancer 109 (2007) 751-760
95. van der Sandt I.C., Gaillard P.J., Voorwinden H.H., de Boer A.G., and Breimer D.D. P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier. Pharm. Res. 18 (2001) 587-592
96. Qin L.J., Gu Y.T., Zhang H., and Xue Y.X. Bradykinin-induced blood-tumor barrier opening is mediated by tumor necrosis factor-alpha. Neurosci. Lett. 450 (2009) 172-175
97. Sood R.R., Taheri S., Candelario-Jalil E., Estrada E.Y., and Rosenberg G.A. Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J. Cereb. Blood Flow Metab. 28 (2008) 431-438
98. Fleegal-DeMotta M.A., Doghu S., and Banks W.A. Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells J. Cereb. Blood Flow Metab. 29 (2009) 640-647
99. Hartmann J.T., and Lipp H.P. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Drug Safety 29 (2006) 209-230
100. Sesti S., Martino G., Mazzulla S., and Chimenti R. Effect of bradykinin on nitric oxide production, urea synthesis and viability of rat hepatocyte cultures. BMC Physiology 5 (2005) 2 10.1186/1472-6793-5-2
101. Poruchynsky M.S., Sackett D.L., Robey R.W., Ward Y., Annunziata C., and Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 7 (2008) 940-949
102. Anderson B.D., Morgan M.E., and Singhal D. Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats. Pharm. Res. 12 (1995) 1126-1133
103. McDannold N., Vykhodtseva N., Raymond S., Jolesz F.A., and Hynynen K. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med. Biol. 31 (2005) 1527-1537
104. Meairs S., and Alonso A. Ultrasound, microbubbles and the blood-brain barrier. Prog. Biophy. Mol. Biol. 93 (2007) 354-362
105. Vykhodtseva N., McDannold N., and Hynynen K. Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics 48 (2008) 279-296
106. Ojewole E., Mackraj I., Naidoo P., and Govender T. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur. J. Pharm. Biopharm. 70 (2008) 697-710
107. Govender T., Ojewole E., Naidoo P., and Mackraj I. Polymeric nanoparticles for enhancing antiretroviral drug therapy. Drug Deliv. 15 (2008) 493-501
108. Spitzenberger T.J., Heilman D., Diekmann C., Batrakova E.V., Kabanov A.V., Gendelman H.E., Elmquist W.F., and Persidsky Y. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J. Cereb. Blood Flow Metab. 27 (2007) 1033-1042
109. Amiji M.M., Vyas T.K., and Shah L.K. Role of nanotechnology in HIV/AIDS treatment: potential to overcome the viral reservoir challenge. Discovery Med. 6 (2006) 157-162
110. Ryan S.M., Mantovani G., Wang X., Haddleton D.M., and Brayden D.J. Advances in PEGylation of important biotech molecules: delivery aspects. Exp. Opin. Drug Deliv. 5 (2008) 371-383
111. Khalil I.A., Kogure K., and Akita H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol. Rev. 58 (2006) 32-45
112. Amyere M., Mettlen M., van der Smissen P., Platek A., Payrastre B., Veithen A., and Courtoy P.J. Origin, originality, functions, subversions and molecular signaling of macropinocytosis. Int. J. Med. Microbiol. 291 (2002) 487-494
113. Kaplan I.M., Wadia J.S., and Dowdy S.F. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Control Release 102 (2005) 247-253
114. Pelkmans L., Kartenbeck J., and Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat. Cell Biol. 3 (2001) 473-483
115. Popovic N., and Brundin P. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Int. J. Pharmaceut. 314 (2006) 120-126
116. Koziara J.M., Lockman P.R., Allen D.D., and Mumper R.J. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control Release 99 (2004) 259-269
117. Alyaudtin R.N., Reichel A., Löbenberg R., Ramge P., Kreuter J., and Begley D.J. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J. Drug Target. 9 (2001) 209-221
118. Gao K., and Jiang X. Influence of particle size on transport of methotrexate across blood-brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharmaceut. 310 (2006) 213-219
119. Alyautdin R., Gothier D., Petrov V., Kharkevich D., and Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 41 (1995) 44-48
120. Olivier J.C. Drug transport to brain with targeted nanoparticles. NeuroRx 2 (2005) 108-119
121. Kuo Y.C., and Chen H.H. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int. J. Pharm. 327 (2006) 160-169
122. Dechy-Cabaret O., Martin-Vaca B., and Bourissou D. Controlled ring-opening polymerization of lactide and glycolide. Chem. Rev. 104 (2004) 6147-6176
123. Leonard D.J., Pick L.T., Farrar D.F., Dickson G.R., Orr J.F., and Buchanan F.J. The modification of PLA and PLGA using electron-beam radiation. J. Biomed. Mater. Res. A 89 (2009) 567-574
124. Lu J.M., Wang X., Marin-Muller C., Wang H., Lin P.H., Yao Q., and Chen C. Current advances in research and clinical applications of PLGA-based nanotechnology. Exp. Rev. Mol. Diagn. 9 (2009) 325-341
125. Gao X., Wu B., Zhang Q., Chen J., Zhu J., Zhang W., Rong Z., Chen H., and Jiang X. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J. Control. Release. 121 (2007) 156-167
126. Kim D.H., and Martin D.C. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials 27 (2006) 3031-3037
127. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharm. 71 (2009) 445-462
128. Huang R.Q., Qu Y.H., Ke YH W.L., Zhu J.H., Pei Y.Y., and Jiang C. Efficient gene delivery targeted to the brain using a transferring-conjugated polyethylene glycol-modified polyamidoamine dendrimer. FASEB J. 21 (2007) 1117-1125
129. Dhanikula R.S., Argaw A., Bouchard J.F., and Hildgen P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol. Pharm. 5 (2008) 105-116
130. Dutta T., and Jain N.K. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly(propyleneimine) dendrimer. Biochim. Biophys. Acta. 1770 (2007) 681-686
131. Gershkovich P., Wasan K.M., and Barta C.A. A review of the application of lipid-based systems in systemic, dermal/transdermal, and ocular drug delivery. Crit. Rev. Ther. Drug Carrier Sys. 25 (2008) 545-584
132. Webb M.S., Rebstein P., Lamson W., and Bally M.B. Liposomal drug delivery: recent patents and emerging opportunities. Recent Patents Drug Delivery Formulation 1 (2007) 185-194
133. Sawant K.K., and Dodiya S.S. Recent advances and patents on solid lipid nanoparticles. Recent Patents Drug Delivery Formulation 2 (2008) 120-135
134. Fresta M., Puglisi G., Di Giacomo C., and Russo A. Liposomes as in vivo carriers for citicoline: effects on rat cerebral post-ischaemic reperfusion. J. Pharm. Pharmacol. 46 (1994) 974-981
135. Anda T., Yamashita H., Fujita H.T., Yoshiharu, and Shibata S. Basic experiment of BBB permeability of cisplatin encapsulated in liposome by means of in vitro BBB. Drug Deliv. Syst. 10 (1995) 425-430
136. Mori N., Kurokouchi A., Osonoe K., Saitoh H., Ariga K., Suzuki K., and Iwata Y. Liposome-entrapped phenytoin locally suppresses amygdaloid epileptogenic focus created by db-cAMP/EDTA in rats. Brain Res. 703 (1995) 184-190
137. Garg M., Asthana A., Agashe H.B., Agrawal G.P., and Jain N.K. Stavudine-loaded mannosylated liposomes: in vitro anti-HIV-I activity, tissue distribution and pharmacokinetics. J. Pharm. Pharmacol. 58 (2006) 605-616
138. Kaur C.D., Nahar M., and Jain N.K. Lymphatic targeting of zidovudine using surface-engineered liposomes. J. Drug Target. 16 (2008) 798-805
139. Dusserre N., Lessard C., Paquette N., Perron S., Poulin L., Tremblay M., Beauchamp D., Desormeaux A., and Bergeron M.G. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics. AIDS 9 (1995) 833-841
140. Zhang X., Xie J., Li S., Wang X., and Hou X. The study on brain targeting of the amphotericin B liposomes. J. Drug Target. 11 (2003) 117-122
141. Vyas T.K., Shahiwala A., and Amiji M.M. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int. J. Pharm. 347 (2008) 93-101
142. Wong H.L., Bendayan R., Rauth A.M., Li Y., and Wu X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 59 (2007) 491-504
143. Muller R.H., Ruhl D., Runge S., Schulze-Forster K., and Mehnert. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surface. Pharm. Res. 14 (1997) 458-462
144. Chattopadhyay N., Zastre J., Wong H.L., Wu X.Y., and Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm. Res. 25 (2008) 2262-2271
145. Kabanov A.V., and Alakhov V.Y. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit. Rev. Ther. Drug Carrier Syst. 19 (2002) 1-72
146. Zhang X., Alakhova D.Y., Batrakova E.V., Li S., Yang Z., Li Y., and Kabanov A.V. Effect of Pluronic p85 on amino acid transport in bovine brain microvessel endothelial cells. J. Neuroimmune Pharmacol. 4 (2009) 35-46
147. Batrakova E.V., Li S., Alakhov V.Y., Miller D.W., and Kabanov A.V. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J. Pharmacol. Exp. Ther. 304 (2003) 845-854
148. Batrakova E.V., Li S., Miller D.W., and Kabanov A.V. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. 16 (1999) 1366-1372
149. ® block copolymers. J. Control. Release 91 (2003) 75-81
150. MacKay J.A., Deen D.F., and Szoka F.C. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res. 1035 (2005) 139-153
151. Lockman P.R., Koziara J.M., Mumper R.J., and Allen D.D. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J. Drug Target. 12 (2004) 635-641
152. Fenart L., Casanova A., Dehouck B., Duhem C., Slupek S., Cecchelli R., and Betbeder D. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J. Pharmacol. Exp. Ther. 291 (1999) 1017-1022
153. Liu F., and Liu D. Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs. Pharm. Res. 12 (1995) 1060-1064
154. Kerwin B.A. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J. Pharm. Sci. 97 (2008) 2924-2935
155. Goppert T.M., and Muller R.H. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J. Drug Target. 13 (2005) 179-187
156. Kreuter J., Ramge P., Petrov V., Hamm S., Gelperina S.E., Engelhardt B., Alyautdin R., von Briesen H., and Begley D.J. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 20 (2003) 409-416
157. Michaelis K., Hoffmann M.M., Dreis S., Herbert E., Alyautdin R.N., Michaelis M., Kreuter J., and Langer K. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharm. Exp. Ther. 317 (2006) 1246-1253
158. Huwyler J., Yang J., and Pardridge W.M. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J. Pharmacol. Exp. Ther. 282 (1997) 1541-1546
159. Jefferies W.A., Brandon M.R., and Hunt S.V. Transferrin receptor on endothelium of brain capillaries. Nature 312 (1984) 162-163
160. Jefferies W.A., Brandon M.R., Williams A.F., and Hunt S.V. Analysis of lymphopoietic stem cells with a monoclonal antibody to the rat transferrin receptor. Immunology 54 (1985) 333-341
161. Olivier J.-., Huertas R., Hwa J.L., Calon F., and Pardridge W.M. Synthesis of pegylated immunonanoparticles. Pharm. Res. 19 (2002) 1137-1143
162. Suzuki T., Wu D., Schlachetzki F., Jian Y.L., Boado R.J., and Pardridge W.M. Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J. Nucl. Med. 45 (2004) 1766-1775
163. Wu D., and Pardridge W.M. Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody. Drug Metab. Dispos. 26 (1998) 937-939
164. Pardridge W.M. Peptide drug delivery across the blood-brain barrier. Proc. West Pharmacol. Soc. 39 (1996) 93
165. Boado R.J., Zhang Y., and Pardridge W.M. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol. Bioeng. 96 (2007) 381-391
166. Chekhonin V.P., Zhirkov Y.A., Gurina O.I., Ryabukhin I.A., Lebedev S.V., Kashparov I.A., and Dmitriyeva T.B. PEGylated immunoliposomes directed against brain astrocytes. Drug Deliv. 12 (2005) 1-6
167. Schnyder A., Krahenbuhl S., Drewe J., and Huwyler J. Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. J. Drug Target. 13 (2005) 325-335
168. Abulrob A., Zhang J., Tanha J., MacKenzie R., and Stanimirovic D. Single domain antibodies as blood-brain barrier delivery vector. Int. Congr. Ser. - Drug Transport(ers) Diseased Brain 1277 (2005) 212-223
169. Abulrob A., Sprong H., Van Bergen en Henegouwen P., and Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J. Neurochem. 95 (2005) 1201-1214
170. Kim J.B., and Sharp PA P.A. Positive transcription elongation factor B phosphorylates hSPT5 and RNA polymerase II carboxyl-terminal domain independently of cyclin-dependent kinase-activating kinase. J. Biol. Chem. 276 (2001) 12317-12312
171. Zheng L., Yang Y.D., Lu G.C., and Salvato S.M. Extracellular HIV Tat and Tat cysteine rich peptide increase CCR5 expression in monocytes. J. Zhejiang Univ. Sci. B 6 (2005) 668-672
172. Derossi D., Calvet S., Trembleau A., Brunissen A., Chassaing G., and Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biol. Chem. 271 (1996) 18188-18193
173. Schwarze S.R., Ho A., Vocero-Akbani A., and Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
174. Sabatier J.M., Vives E., Mabrouk K., Benjouad A., Rochat H., Duval A., Hue B., and Bahraoui E. Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J. Virol. 65 (1991) 961-967
175. Kravcik S., Gallicano K., Roth V., Cassol S., Hawley-Foss N., Badley A., and William C.D. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J. Acquir. Immune Defic. Syndr. 21 (1999) 371-375
176. Wei B., Wei Y., Zhang K., Wang J., Xu R., Zhan S., Lin G., Wang W., Liu M., Wang L., Zhang R., and Li J. Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell penetrating peptide. Biomed. Pharmacother. 63 (2008) 313-318
177. Ganguly S., Chaubey B., Tripathi S., Upadhyay A., Neti P.V., Howell R.W., and Pandey V.N. Pharmacokinetic analysis of polyamide nucleic-acid-cell penetrating peptide conjugates targeted against HIV-1 transactivation response element. Oligonucleotides 18 (2008) 277-286
178. Zhu W.L., and Shin S.Y. Antimicrobial and cytolytic activities and plausible mode of bactericidal action of the cell penetrating peptide penetratin and its lys-linked two-stranded peptide. Chem. Biol. Drug Design 73 (2009) 209-215
179. Vives E. Present and future of cell-penetrating peptide mediated delivery systems: is the Trojan horse too wild to go only to Troy. J. Control. Release 109 (2005) 77-85
180. Dou H., Morehead J., Destache C.J., Kingsley J.D., Shlyakhtenko L., Zhou Y., Chaubal M., Werling J., Kipp J., Rabinow B.E., and Gendelman H.E. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte derived macrophages. Virology 358 (2007) 148-158
181. Illum L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems. J. Pharm. Sci. 96 (2007) 473-483
182. Gao X., Tao W., Lu W., Zhang Q., Zhang Y., Jiang X., and Fu S. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials 27 (2006) 3482-3490
183. Ruff M.R., Polianova M., Pert C.B., and Ruscetti F.W. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res. 52 (2001) 63-75
184. Wong H.L., Rauth A.M., Bendayan R., and Wu X.Y. Combinational treatment with doxorubicin and GG918 (Elacridar) using polymer-lipid hybrid nanoparticles (PLN) and evaluation of strategies for multidrug-resistance reversal in human breast cancer cells. J. Control. Release 116 (2006) 275-284
185. Wong H.L., Bendayan R., Rauth A.M., and Wu X.Y. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci. 93 (2004) 1993-2004
186. Lee Y.J., Maeda J., Kusuhara H., Okauchi T., Inaji M., Nagai Y., Obayashi S., Nakao R., Suzuki K., Sugiyama Y., and Suhara T. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in non human primates using [11C] verapamil. J. Pharmacol. Exp. Ther. 316 (2006) 647-653
187. Ulbrich K., Hekmatara T., Herbert E., and Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm. 71 (2009) 251-256
188. Boado R.J., Zhang Y., Zhang Y., and Pardridge W.M. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol. Bioengin. 96 (2007) 381-391
189. Giovannoni G., Miller R.F., Heales S.J.R., Land J.M., Harrison M.J.G., and Thompson E.J. Elevated cerebrospinal fluid and serum nitrate and nitrite levels in patients with central nervous system complications of HIV-1 infection: a correlation with blood-brain-barrier dysfunction. J. Neurol. Sci. 156 (1998) 53-58
190. Petito C.K., and Cash K.S. Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmortem brain. Ann. Neurol. 32 (1992) 658-666
191. Toborek M., Lee Y.W., Flora G., Pu H., András I.E., Wylegala E., Hennig B., and Nath A. Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol. Neurobiol. 25 (2005) 181-199
192. Caliceti P., and Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 55 (2003) 1261-1277
193. Soni S., Babbar A.K., Sharma R.K., Banerjee T., and Maitra A. Pharmacoscintigraphic evaluation of polysorbate80-coated chitosan nanoparticles for brain targeting. Amer. J. Drug Del. 3 (2005) 205-212
194. Soni V., Jain S.K., and Kohli D.V. Potential of transferrin and transferrin conjugates of liposomes in drug delivery and targeting. Amer. J. Drug Deliv. 3 (2005) 155-170